Literature DB >> 11562884

Advanced oropharyngeal carcinoma treated with surgery and radiotherapy: oncologic outcome and functional assessment.

A S Denittis1, M Machtay, D I Rosenthal, N J Sanfilippo, J H Lee, S Goldfeder, A A Chalian, G S Weinstein, R S Weber.   

Abstract

INTRODUCTION/
PURPOSE: Surgery and postoperative radiotherapy (XRT) is a standard therapy for locally advanced resectable oropharyngeal carcinoma. This maximizes local-regional control, but does not address the potential for occult distant metastases. Additionally, some patients may suffer poor functional outcome after this intensive local therapy. This report reviews our institutional experience with modern radical surgery and XRT for this disease.
METHODS: A retrospective chart review was performed on 51 consecutive patients treated from 1991 to 1997 at the University of Pennsylvania with radical surgery and postoperative XRT. This study included patients with locally advanced, stage III/IV (exclusive of T1-2N1) squamous carcinoma of the oropharynx. All patients had a good performance status (ECOG 0-1). Patients who received adjuvant chemotherapy were excluded. No patient had gross residual disease after surgery; the median XRT dose was 63.7 Gy. Survival, local-regional control (LRC), and freedom from distant metastases (DM) were calculated actuarially. In patients who remained free of disease, functional status was determined using the List Performance Status Scale (PSS).
RESULTS: With a median follow-up in surviving patients of 34 months, the 3-year actuarial overall survival was 51%. The 3-year LRC was 73%, and the freedom from DM was 69%. The most significant factor predicting for failure was the number of pathologically positive nodes (P <.001 for survival and DM; P =.003 for LRC). In 29 patients who were evaluable for the List PSS, the mean normalcy-of-diet score was 48; the mean eating-in-public score was 53; and the mean understandability-of-speech score was 75. There was a trend toward better PSS scores in patients with T1-2 tumors versus T3-4 tumors, although this did not reach statistical significance.
CONCLUSIONS: Surgery and postoperative XRT offer relatively good LRC and moderate overall survival rates. Results, however, remain suboptimal, particularly with respect to the risk of DM and the functional outcome. These data provide a baseline for comparison with maturing results from multimodality trials in which radical surgery is not used in all patients with locally advanced oropharyngeal carcinoma.

Entities:  

Mesh:

Year:  2001        PMID: 11562884     DOI: 10.1053/ajot.2001.26492

Source DB:  PubMed          Journal:  Am J Otolaryngol        ISSN: 0196-0709            Impact factor:   1.808


  12 in total

1.  Oncologic and functional results after transoral laser microsurgery of tongue base carcinoma.

Authors:  Martin Canis; Friedrich Ihler; Hendrik A Wolff; Hans Christiansen; Christoph Matthias; Wolfgang Steiner
Journal:  Eur Arch Otorhinolaryngol       Date:  2012-07-05       Impact factor: 2.503

2.  When is definitive radiotherapy the preferred treatment for head and neck squamous cell carcinoma?

Authors:  William M Mendenhall; Primož Strojan; Avraham Eisbruch; Robert Smee; Alessandra Rinaldo; Alfio Ferlito
Journal:  Eur Arch Otorhinolaryngol       Date:  2015-05-30       Impact factor: 2.503

3.  The (head and neck) carcinologic handicap index: validation of a modular type questionnaire and its ability to prioritise patients' needs.

Authors:  Mathieu Balaguer; Maëlle Champenois; Jérôme Farinas; Julien Pinquier; Virginie Woisard
Journal:  Eur Arch Otorhinolaryngol       Date:  2020-07-14       Impact factor: 2.503

4.  An exploratory study of the influence of clinico-demographic variables on swallowing and swallowing-related quality of life in a cohort of oral and oropharyngeal cancer patients treated with primary surgery.

Authors:  Raghav C Dwivedi; Edward J Chisholm; Afroze S Khan; Nicholas J Harris; Shree A Bhide; Suzanne St Rose; Cyrus J Kerawala; Peter M Clarke; Christopher M Nutting; Peter H Rhys-Evans; Kevin J Harrington; Rehan Kazi
Journal:  Eur Arch Otorhinolaryngol       Date:  2011-09-10       Impact factor: 2.503

5.  Definitive radiochemotherapy or initial surgery for oropharyngeal cancer : To what extent can p16 expression be used in the decision process?

Authors:  Anouchka Modesto; Thibaut Galissier; Amélie Lusque; Jean-Pierre Delord; Emmanuelle Uro-Coste; Jérôme Sarini; Frédéric Mouchet; Raphaël Lopez; Anne Laprie; Pierre Graff; Sébastien Vergez; Michel Rives
Journal:  Strahlenther Onkol       Date:  2019-03-15       Impact factor: 3.621

6.  Transoral robotic surgery in management of oropharyngeal cancers: a preliminary experience at a tertiary cancer centre in India.

Authors:  Surender Dabas; Abhinav Dewan; Reetesh Ranjan; Ajay Kumar Dewan; Anoop Puri; Swati H Shah; Rupal Sinha
Journal:  Int J Clin Oncol       Date:  2014-12-17       Impact factor: 3.402

7.  Factors influencing intelligibility and severity of chronic speech disorders of patients treated for oral or oropharyngeal cancer.

Authors:  Mathieu Balaguer; Aline Boisguerin; Anaïs Galtier; Nadège Gaillard; Michèle Puech; Virginie Woisard
Journal:  Eur Arch Otorhinolaryngol       Date:  2019-03-27       Impact factor: 2.503

8.  Respiratory-swallow phase patterns and their relationship to swallowing impairment in patients treated for oropharyngeal cancer.

Authors:  Martin B Brodsky; David H McFarland; Thomas S Dozier; Julie Blair; Christopher Ayers; Yvonne Michel; M Boyd Gillespie; Terry A Day; Bonnie Martin-Harris
Journal:  Head Neck       Date:  2010-04       Impact factor: 3.147

9.  Morbidity, mortality and cost from HPV-related oropharyngeal cancer: Impact of 2-, 4- and 9-valent vaccines.

Authors:  Greg Ward; Vikas Mehta; Michael Moore
Journal:  Hum Vaccin Immunother       Date:  2015-11-13       Impact factor: 3.452

10.  Developing core sets for patients with head and neck cancer based on the International Classification of Functioning, Disability and Health (ICF).

Authors:  U Tschiesner; A Cieza; S N Rogers; J Piccirillo; G Funk; G Stucki; A Berghaus
Journal:  Eur Arch Otorhinolaryngol       Date:  2007-06-14       Impact factor: 3.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.